<DOC>
	<DOCNO>NCT02122146</DOCNO>
	<brief_summary>To assess safety tolerability increase dose level PF-06664178 patient advance solid tumor order determine maximum tolerate dose select recommend Phase 2 dose .</brief_summary>
	<brief_title>A Study Of PF-06664178 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Diagnosis solid tumor advanced/metastatic resistant standard therapy standard therapy available Performance Status 0 1 Adequate bone marrow , kidney liver function Part 2 include target express NSCLC , ovarian breast cancer patient Brain metastasis require steroid Major surgery , radiation therapy , systemic anticancer therapy within 4 week study treatment start ( 6 week mitomycin C nitrosoureas ) Active clinically significant bacterial , fungal , viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ADC</keyword>
	<keyword>PF-06664178</keyword>
	<keyword>solid tumor</keyword>
	<keyword>tumor</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>NSCLC</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>OVCA</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>breast cancer</keyword>
</DOC>